Health Action International launches new Brussels office

BRUSSELS—Health Action International, the only non-governmental organisation entirely dedicated to strengthening pharmaceutical policy to improve public health, today announced the opening of a new office in Brussels, Belgium.

“This expansion is an important step in truly bringing our message of equitable medicines access to the heart of the European Union,” said Tim Reed, executive director of Health Action International. “It reflects our ambition to further increase our influence in the rapidly-evolving medicines policy arena.”

Aliénor Devalière, one of three policy advisors at Health Action International that focus on European Union pharmaceutical policy, is leading the establishment of the Brussels office.

Tessel Mellema, who specialises in trade, innovation, intellectual property and access to medicines, and Ancel.la Santos Quintano, who covers rational use and good governance of medicines, will continue to be based in Health Action International’s Amsterdam headquarters.

“Our new location will put us in the thick of policy developments as they happen and allow us to work more closely with partners and policy-makers,” said Devalière. “This will enable us to extend the reach and effectiveness of our advocacy to improve access to affordable, needed medicines.”

The new Health Action International office is located at Rue de l’Arbre Bénit 44 / Gewijde-Boomstraat 44. The phone number is +32 2 486 01 79.

About Health Action International
Health Action International is the only non-governmental organisation entirely dedicated to strengthening pharmaceutical policy to improve public health. Our staff and global network of members have unparalleled expertise in virtually all areas of medicines policy, including the price, availability and affordability of medicines, clinical data transparency, intellectual property and pharmaceutical marketing. We pursue advocacy at the patient level and up to the highest levels of government through our ‘official relations’ status with the World Health Organization and respected relationship with the European Medicines Agency. We are financially independent from the pharmaceutical industry.

For comment and additional information:
Aliénor Devalière
Policy Advisor, Equitable Access and Trade
Health Action International
Telephone: +32 2 486 01 79
Email: alienor@haiweb.org
Web: www.haieurope.org

- END -